Advertisement

New Guidelines for HER2-Negative Advanced Breast Cancer — Physician’s First Watch

Medical News |
September 3, 2014

New Guidelines for HER2-Negative Advanced Breast Cancer

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

The American Society of Clinical Oncology has released new guidelines on managing advanced human epidermal growth factor receptor (HER2)-negative breast cancer. Among the recommendations:

  • For most patients with hormone-receptor-positive advanced breast cancer, endocrine treatment should be the first-line therapy.

  • Sequential single-agent chemotherapy regimens should be offered, but combination treatments may be given if the disease is immediately life-threatening.

  • The use of bevacizumab is controversial given that it improves treatment response but not overall survival when added to single-agent chemotherapy.

  • For first-line chemotherapy, taxanes and anthracyclines have the strongest evidence for efficacy.

  • Chemotherapy should not at this time be targeted to specific cancer subtypes.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement